Over the past few years we’ve seen a remarkable swell in the amount of money that’s been coursing through the biotech industry. Last year the US and other hubs racked up record amounts of venture cash being injected into startups as the IPO boom reached a crescendo. And even after the market swooned, we’re still seeing a steady stream of life science companies lining up to go public while venture investing continues at only a slightly slower pace.
For biotech’s top hubs—places like Boston/Cambridge, the Bay Area, and the Golden Triangle in the UK—there’s never been a better time to line up funding and tackle a new drug. And some new regions, like New York and Shanghai, are making a serious bid to join the list of emerging hubs. Experienced teams, some led by serial entrepreneurs or the execs leaving big pharma and biotech, can be recruited and fielded in a matter of months. (more…)